Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406508 | 0.83 | MAPK1 (0.44) | MAPK1ATMS1PR3KDM4EL3MBTL1 | |
| SCHEMBL22919199 | 0.83 | MAPK1 (0.44) | MAPK1ATMS1PR3KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3654463 | 0.82 | MAPK1 (0.41) | MAPK1ATMS1PR4S1PR3P2RY12 | |
| SCHEMBL14992833 | 0.81 | MAPT (0.43) | MAPK1ATMKDM4EL3MBTL1MAPT | |
| SCHEMBL25047559 | 0.80 | HCAR2 (0.43) | MAPK1KDM4EPOLBKMT2AALDH1A1 | |
| SCHEMBL4534363 | 0.79 | MAPK1 (0.41) | MAPK1ATMS1PR4S1PR3P2RY12 | |
| SCHEMBL473919 | 0.78 | ALDH1A1 (0.51) | MAPK1ATMP2RY12KDM4EL3MBTL1 | |
| SCHEMBL29726958 | 0.78 | ALDH1A1 (0.51) | MAPK1ATMP2RY12KDM4EL3MBTL1 | |
| SCHEMBL18940419 | 0.78 | MAPK1 (0.42) | MAPK1ATMS1PR4S1PR3P2RY12 | |
| SCHEMBL198706 | 0.77 | MAPK1 (0.47) | MAPK1ATMS1PR4S1PR3P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117460722-A | Nicotinamide RIPK1 inhibitors | 艾伯维公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | ABBVIE INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | ABBVIE INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | ABBVIE INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023018643-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | RIPK1, RIPK2, RIPK4 | MAPK1 202/4885ATM 4501/4885S1PR4 1043/4885 |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | RIPK1, RIPK2, RIPK4 | MAPK1 202/4885ATM 4501/4885S1PR4 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.